Table 2.
Pretreatment CA15.3 and CEA distribution by clinical characteristics of interest.
| Variable | CA15.3 | p value | CEA | p value |
|---|---|---|---|---|
| Endocrine-resistance patterns | ||||
| Primary | 55.2 (30–171) | 0.930 | 6.6 (2.5–15.9) | 0.653 |
| Secondary | 60.7 (29–138.7) | 4.4 (1.85–11.85) | ||
| Metastatic at diagnosis | 58.94 (28.78–146) | 4.6 (2.25–15.35) | ||
| Site of metastasis | ||||
| Visceral | 51 (29–119.47) | 0.596 | 5.9 (2.3–12.43) | 0.596 |
| Non-visceral | 73 (28.38–160.12) | 5 (1.8–13.85) | ||
| Line of treatment | ||||
| 1 | 76.3 (36.55–172) | 0.020* | 6.5 (2.1–19.2) | 0.122 |
| ≥2 | 53.9 (25.5–97.32) | 4.6 (1.96–9.45) | ||
Marker distribution is described in terms of median value (interquartile range). p values from biomarker analysis are derived from the two-sided Wilcoxon rank-sum test or the Kruskal test.
*
p<0.05.